C. difficile and S. aureus quarterly reports

C.difficle surveillance report quarter July-September 2015 .pdf C.difficle surveillance report quarter April-June 2015.pdf C.difficle surveillance report quarter January - March 2015.pdf C.difficle surveillance report quarter ending Oct - Dec 2014.pdf C.difficle surveillance report quarter ending July - Sept 2014.pdf C.difficle sureillance report quarter ending April - June 2014.pdf C.difficle surveillance report quarter endin January - March 2014.pdf C.difficle surveillance report quarter ending October to December 2013.pdf C.difficle surveillance report quarter ending 1st July 2013 to 30th September 2013.pdf C.difficle surveillance report quarter ending 1 April 2013 to 30 June 2013.pdf C.difficle Surveillance Report Quarter Ending 31st March 2013.pdf.pdf C.difficle Surveillance Report Quarter Ending 31st December 2012.pdf C.difficile Surveillance Report quarter ending 30 September 2012.pdf.pdf� C.difficile Surveillance Report quarter ending 30 June 2012.pdf C.difficile Surveillance Report quarter ending March 2012 C.difficile Surveillance Report quarter ending December 2011 C.difficile Surveillance Report quarter ending September 2011.pdf C. difficle Surveillance Report quarter ending June 2011.pdf C. difficile Surveillance Report quarter ending March 2011 (930KB).pdf CDI_Report Oct-Dec 2010_2.pdf Staphylococcus aureus S.aureus bacteraemia surveillance quart July-September 2015.pdf S.aureus surveillance report quarter April-June 2015.pdf S.aureus surveillance report quarter January - March 2015.pdf S.aureus surveillance report quarter Oct - Dec 2014.pdf S.aureus sureveillance report quarter July - Sept 2014.pdf S.aureus surveillance report quarter April - June 2014.pdf S. aureus surveillance report quarter January - March 2014.pdf S. aureus surveillance report quarter ending October to December 2013.pdf S. aureus surveillance report quarter ending 1st July 2013 to 30th September 2013.pdf S. aureus surveillance report quarter ending 1 April 2013 to 30 June 2013 S.aureus Surveillance Report Quarter Ending 31st March 2013.pdf.pdf S.aureus Surveillance Report Quarter Ending 31st December 2012.pdf S.aureus Surveillance Report quarter ending 30 September 2012.pdf.pdf S.aureus Surveillance Report quarter ending 30 June 2012.pdf S.aureus Surveillance Report quarter ending March 2012 S.aureus Surveillance Report quarter ending�December 2011 S.aureus Surveillance Report quarter ending September 2011.pdf S.aureus Surveillance Report quarter ending June 2011.pdf S.aureus Surveillance Report quarter ending March 2011 (999KB).pdf Surgical site infectionCumulative incidence of SSI within 30 days after Caesarean section, Reporting Year 2009 (post-discharge excluded) Cumulative incidence of SSI within 30 days after hip prosthesis, Reporting Year 2009 (post-discharge excluded) Cumulative incidence of SSI within 30 days after knee prosthesis, Reporting Year 2009 (post-discharge excluded) � �

A Cluster Randomised Controlled Trial to Evaluate a Policy of Making Hip Protectors Available to Residents of Nursing Homes

Objectives: to evaluate the effectiveness of a policy of making hip protectors available to residents of nursing homes. Design: a cluster randomised controlled trial of the policy in nursing and residential homes, with the home as the unit of randomisation. Setting: 127 nursing and residential homes in the greater Belfast area of Northern Ireland. Participants: 40 homes in the intervention group (representing 1,366 occupied beds) and 87 homes in the control group (representing 2,751 occupied beds). Interventions: a policy of making hip protectors available free of charge to residents of nursing homes and supporting the implementation process by employing a nurse facilitator to encourage staff in the homes to promote their use, over a 72-week period. Main outcome measures: the rate of hip fractures in intervention and control homes, and the level of adherence to use of hip protectors. Results: there were 85 hip fractures in the intervention homes and 163 in the control homes. The mean fracture rate per 100 residents was 6.22 in the intervention homes and 5.92 in the control homes, giving an adjusted rate ratio for the intervention group compared to the control group of 1.05 (95% CI 0.77, 1.43, P = 0.76). Initial acceptance of the hip protectors was 37.2% (508/1,366) with adherence falling to 19.9% (272/1,366) at 72 weeks.Conclusions: making hip protectors available to residents of nursing and residential homes did not reduce the rate of hip fracture. This research does not support the introduction of a policy of providing hip protectors to residents of nursing homes.